Sign up
Pharma Capital

Invion’s non-dilutive funding arrangement allows full focus on developing cancer treatments

Invion Ltd (ASX:IVX) managing director & CEO Greg Collier speaks to Proactive Investors about the biotech company’s development of treatments for chronic inflammatory and autoimmune diseases, as well as the transformational funding arrangements put in place over the last 12 months.
 
“We set up an R&D agreement with the Cho Group and that means that the Cho Group are funding all our research and development, all our clinical research, in a non-dilutive fashion,” Collier says.
 
He continues, “so this is pretty unusual for a biotech company, we don’t have to raise capital.”
 
Invion is planning to spin-out its respiratory assets into a new public unlisted company to better concentrate on its cancer treatments, giving Invion shareholders equal holding in the proposed company.
 

View full IVX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.